Kepos Capital’s Starling Oncology, Inc. Warrant STLNW Stock Holding History

Kepos Capital’s Portfolio STLNW Stock Details STLNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-150,000	Closed	-$211K	–	673
2021 Q3	$211K	Hold	150,000	–	–	0.01%	458
2021 Q2	$260K	Buy	+150,000	New	+$202K	0.02%	379
2021 Q1	–	Sell	-57,500	Closed	-$112K	–	444
2020 Q4	$112K	Sell	57,500 -37,500	-39%	-$64.7K	0.01%	313
2020 Q3	$161K	Buy	+95,000	New	+$156K	0.02%	218

Other funds holding STLNW

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

DCM

Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return

USPCM

Union Square Park Capital Management New York $176M AUM 51.52% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Kepos Capital's STLNW Position: Q4 2021 in Review

Kepos Capital sold out of Starling Oncology, Inc. Warrant (STLNW) in Q4 2021, closing a stake of 150,000 shares — an estimated $211K sold.

Kepos Capital first reported a position in STLNW in Q3 2020 and held it in 4 quarters. The position peaked at $260K in Q2 2021. 20 funds tracked by Wall St. Rank hold STLNW as of Q4 2021.

Kepos Capital reported no remaining Starling Oncology, Inc. Warrant position as of Q4 2021 after selling out during the quarter.
Kepos Capital sold 150,000 Starling Oncology, Inc. Warrant shares in Q4 2021, an estimated $211K.
Kepos Capital first reported a position in Starling Oncology, Inc. Warrant in Q3 2020 and held it in 4 quarters.
Kepos Capital's Starling Oncology, Inc. Warrant position peaked at $260K in Q2 2021.
20 funds tracked by Wall St. Rank held Starling Oncology, Inc. Warrant as of Q4 2021.

Based on Kepos Capital's 13F filing for Q4 2021, filed 14 Feb 2022.